Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin + Tislelizumab in R/R CD30+ NK/T-cell Lymphoma
NCT05316246Phase 2Unknown
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jun 2022
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 2 trial of brentuximab vedotin, tislelizumab in Natural killer T-cell lymphoma (NKTL), sponsored by Zhongshan Hospital, Fudan University. Status: unknown.
02
Drugs
brentuximab vedotintislelizumab
03
Conditions
Natural killer T-cell lymphoma (NKTL)
Beyond the preview
Go deeper on NCT05316246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05316246.